Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8552W HIGH $4.87
Volume
61.50 K
Value Traded
27.33 K
Short % Float
0.26%
+0.97%Week
-18.11%1 Month
-41.57%3 Month
-69.32%6 Month
-92.54%5 Year
-99.85%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
12.84 M
EPS (TTM)
-1.93
P/E Ratio
-
Ent. Value
5.03 M
Total Shares
12.34 M
Float Shares
7.55 M
Insiders
38.86%
Institutions
11.06%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PLUR Catalyst Timeline
Dated clinical, regulatory and corporate events for Pluri Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pluri Inc.
756Total events
4Upcoming
159Tier-1 (high impact)
2009 to 2027Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Pricing of $3.3 million registered direct offering and concurrent private placement
▲Other Regulator MilestoneRegenativoFiledEx-US Regulatory
UK cosmetic regulatory registration completed for Regenativo+
regenerative aestheticssource ↗
▲Product LaunchRegenativoFiledPost-Market
Commercial launch of Regenativo+ in UK
regenerative aestheticssource ↗
▲Partnership / LicenseCorporate
Pluristyx announces collaboration with WFIRM, Innovian Space, and ReMDO to develop clinical-grade hepatocyte manufacturing
▲Patent GrantedIP / Competition
Japanese Patent Office issued Notice of Allowance for patent application covering synthetic mRNA technology
▲FDA Filing AcceptedRegenativoFiledRegulatory Filing
U.S. cosmetic product listing completed
regenerative aestheticssource ↗
▲FDA Filing AcceptedPlacentoFiledRegulatory Filing
U.S. cosmetic product listing completed
regenerative aestheticssource ↗
▲Patent GrantedIP / Competition
China patent grant for large-scale immune cell expansion technology
▲Manufacturing MilestoneCMC / Inspection
Completion of first phase of Resbiomed program (initial process development and feasibility)
◆Product LaunchPost-Market
First product under Miss Universe Skincare label expected to launch
▲Patent GrantedStemLoopIP / Competition
Allowance of patents for proprietary StemLoop mRNA reprogramming technology
▲Patent GrantedIP / Competition
Allowance of patents for proprietary iACT Stealth immune-cloaking technology
▲Manufacturing MilestoneCMC / Inspection
Successful engineering runs and clinical-grade manufacturing of Remedy Cell's lead candidate
▲Partnership / LicenseCorporate
Expansion of manufacturing agreement between Pluri and Remedy Cell
▼Equity OfferingCorporate
Private placement of 625,000 shares and warrants to Weinstein entity for $2.5M gross proceeds
▲Other Regulator MilestoneEx-US Regulatory
CEO Yaky Yanay expected to accept Egalitarian Employment Award from Minister Nir Barkat
▲Other Regulator MilestoneEx-US Regulatory
Pluri named Overall BioAgriculture Company of the Year by Biotech Breakthrough Awards
▲Partnership / LicenseCorporate
Pluri partners with Miss Universe Skincare for co-development of cell-based skincare products
●Oral PresentationPresentation
Official presentation of collaboration at pre-gala activities of 74th Miss Universe event in Thailand
▲Other Regulator MilestoneEx-US Regulatory
Kokomodo Ltd. selected as MassChallenge Switzerland 2025 Award gold winner
▲Timing GuidancePresentation
Anticipate coming fiscal year (FY2026) as significant turning point for cell expansion technology in cocoa and coffee
▲Partnership / LicenseCorporate
Pluri enters agreement with Resbiomed for placenta-derived biomaterials program
▲Quarterly UpdateCorporate
Nearly 400% revenue growth in first nine months of fiscal year 2025 vs same period fiscal 2024
▲Partnership / LicenseCorporate
Secured additional investment from a new partner with healthcare expertise and emerging markets track record
▼Program DiscontinuationCorporate
Federal budget cuts discontinued NIH/DoD funding for PLX-R18 ARS program
▲Timing GuidancePresentation
Expect revenue growth to continue as commercial efforts gain traction
▲Patent GrantedIP / Competition
US patent granted for immune cell expansion technologies including MAIT cells
▲Partnership / LicensePLX-R18FiledCorporate
Exclusive collaboration agreement with Hemafund for PLX-R18 stockpiling and distribution in Ukraine
Hematopoietic Acute Radiation Syndrome (H-ARS)source ↗
▼Equity OfferingCorporate
Pricing of $3.5 million private placement with Merchant Adventure Fund
▼Equity OfferingCorporate
Pluri secures $6.5M strategic investment led by Alejandro Weinstein
◆Poster PresentationPresentation
PluriCDMO shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025
▲Other Regulator MilestoneEx-US Regulatory
Pluri listed on Dun's 100 list of Best HighTech Companies to work for in 2025
◆First Patient DosedRC-0315Trial
First in human expected early 2025 for RC-0315
Idiopathic Pulmonary Fibrosissource ↗
●Manufacturing MilestonePLX-R18FiledCMC / Inspection
Assessing readiness for mass production of PLX-R18
hematopoietic complications of acute radiation syndrome (H-ARS)source ↗
▲Partnership / LicenseCorporate
Pluri collaborates with Bar-Ilan University to advance MAIT cell therapy for solid tumors, funded by Israel Innovation Authority
solid tumorssource ↗
▲Partnership / LicenseCorporate
PluriCDMO signs tech transfer and manufacturing agreement with Kadimastem for AstroRx and IsletRx
▲Partnership / LicenseCorporate
€1 million proof of concept agreement with leading international agriculture corporation
sustainable vegetable supplysource ↗
▲Equity OfferingCorporate
Ever After Foods secured $10 million strategic investment from U.S. and EU investors
▲Partnership / LicenseCorporate
Pluri extended license field granted to Ever After Foods to include cultivated fish
▲Equity OfferingCorporate
Ever After Foods Ltd. raised $10 million funding round led by two international strategic partners
Past FDA Catalysts and PDUFA Decisions
How PLUR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D24 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 86%
Micro Cap(rank 566 of 658)
Percentile Rank
Pluri Inc. faces pipeline headwinds (24/100), with $79M risk-adjusted pipeline value, led by PLX-R18 in Incomplete HCT (Hematopoietic Cell Transplantation) (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PLX-R18 Monoclonal antibodyCompletedNCT03002519 | Incomplete HCT (Hematopoietic Cell Transplantation) | Phase 1 | COMPLETED | 21 | Oct 30, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every PLUR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PLX-PAD | muscle injury following arthroplasty for hip fracture | Phase 3 | 2022-07-13 | 3.2kg from reference (week 6) to week 26 compared to 1.3kg in the placebo group, a 2kg difference (p=0.047); 5.01kg from reference (week 6) to week 52 compared to 0.86kg in the placebo group, a 4kg difference (p=0.0022); 2.3kg from reference (week 6) to week 26 compared to 0.51kg in the placebo group, a 1.8kg difference (p=0.073); 3.3kg from reference (week 6) to week 52 compared to a decrease of 0.7kg in the placebo group, a 4kg difference (p=0.0046); 296 meters versus only 266 meters in placebo treated patients in the 6-minute walk testRead More | Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture SurgeryRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Manieu Alexandre WeinsteinDirector, 10% Owner | Grant/Award | 641 6,925 held | $0.00 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PLUR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PLUR for Q2 2026. | ||||
PLUR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PLUR ranks across every disease it competes in
Competitive Position is a premium feature
See how PLUR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPLUR News
PLURPluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor
Pluri Inc. has announced a registered direct offering and concurrent private placement, raising approximately $3.3 million by selling 2,228,940 common shares at $1.50 each. The offering is expected to close on August 28, 2026, and proceeds will be used for working capital. The company is also issuing unregistered warrants with an exercise price of $1.65.
Read more →PLURPluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment
Pluri Inc. announced that its subsidiary, Ever After Foods, has acquired Fishway, a Belgium-based biotechnology company specializing in aquatic cell biology. This acquisition, along with a $2 million strategic investment, aims to enhance Ever After Foods' cultivated-protein platform and expand its capabilities in the European market. The move is expected to strengthen the company's ability to support scalable production for food and ingredient companies.
Read more →PLURPluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
Pluri Inc. has announced the successful regulatory registration of its subsidiary Cellav's regenerative aesthetics product, Regenativo+, in the UK. This registration supports the upcoming commercial launch in a market valued at approximately $900 million. The move is part of Pluri's broader strategy to expand its global footprint in regenerative aesthetics and longevity markets, following similar regulatory progress in the U.S.
Read more →PLUR▼ -7.9%on this newsshared move
Pluristyx Partners With Leading Regenerative Medicine and Aerospace Pioneers to Standardize Clinical-Grade Hepatocyte Manufacturing for Space and Earth Applications
Pluristyx, in collaboration with Wake Forest Advocate Health and other partners, is developing a standardized clinical-grade hepatocyte manufacturing workflow. This initiative aims to create a scalable supply chain for liver cells, supporting bridge-to-transplantation therapies. The project aligns with NASA's In-Space Production Applications program, enhancing regenerative medicine for both Earth and space applications.
Read more →PLURPluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
Pluri Inc. Chairman Alejandro Weinstein has invested over $17 million, increasing his ownership to more than 30%. This investment reflects his confidence in Pluri's transition from development to commercial operations, particularly in longevity and tailored biologics. The company is experiencing strong interest from U.S. parties for potential collaborations and product purchases.
Read more →PLURPluristyx Inc. Secures Initial Close of Series A Priced Round with Multinational Fortune 500 Company; Round to Remain Open for Syndicate Partners Until September 2nd
Pluristyx Inc. has announced the Initial Close of its Series A financing, led by a Fortune 500 company and supported by existing investors. The investment round will remain open until September 2, 2026, allowing for further participation from institutional and strategic investors. This funding will facilitate the company's expansion and support its innovative iPSC technologies.
Read more →PLURPluristyx Announces Patent Allowance of Next Generation Synthetic mRNA Technology in Japan, Solidifying Global iPSC Reprogramming Leadership
Pluristyx has received a Notice of Allowance from the Japanese Patent Office for its innovative synthetic mRNA technology, which enhances protein expression and stabilizes mRNA. This advancement is crucial for the commercialization of induced pluripotent stem cell (iPSC) therapies in Japan, a leader in regenerative medicine. The technology streamlines the reprogramming process, significantly reducing production time for clinical-grade iPSCs.
Read more →PLURPluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
Pluri Inc. has announced the completion of U.S. cosmetic product listings for its regenerative aesthetic products, Regenativo+ and Placento+, through its subsidiary Cellav. The company is preparing for a commercial launch in the U.S. market, which is projected to grow significantly. Clinical validation supports the efficacy of the products, and discussions with distributors are underway. However, the products are not FDA approved and face regulatory requirements.
Read more →PLURPluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
Pluri Inc. announced that Alejandro Weinstein, its Chairman, has made an additional $2.5 million investment at a 30% premium to market price. This follows a previous investment and highlights Weinstein's continued support for the company's growth strategy. The funds from this private placement, amounting to approximately $2.5 million, will be used for general working capital. The transaction involves the sale of common shares and warrants, with an emphasis on enhancing shareholder value through focused execution.
Read more →PLURPluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent
Pluri Inc. has been granted a patent by the China National Intellectual Property Administration for its 3D immune cell expansion and activation technology. This patent complements previously secured patents in the U.S., Japan, Korea, Australia, and Israel, strengthening Pluri's global intellectual property portfolio. The technology enables scalable and automated manufacturing of diverse immune cell therapies, positioning Pluri to capitalize on the rapidly growing cell therapy market in China. This strategic expansion is expected to support cross-border partnerships and global collaborations, contributing to the company's efforts in enhancing cost-efficiency and maintaining quality control in cell production.
Read more →PLUR▲ +9.3%on this news
Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials
Pluri, Inc. has announced the successful completion of the first phase of its program with Resbiomed Technologies, focusing on the production of placenta-derived biomaterials. The collaboration leverages Pluri's proprietary bioprocessing expertise to enhance the quality and scalability of these materials for use in regenerative medicine. Both companies are now prepared to advance to the next phase of the project, which aims to refine manufacturing processes and ensure consistent quality. This milestone underscores the increasing demand for PluriCDMO services in the biotech sector.
Read more →PLURPluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
Pluri, Inc. has expanded its collaboration with Remedy Cell Ltd. by successfully implementing clinical-grade manufacturing processes at Pluri's GMP facility. This achievement includes the completion of engineering runs and the production of clinical-grade batches for Remedy Cell's initial Phase 1b clinical trial, marking significant progress in developing secretome-based therapies for fibrotic diseases. Both companies expressed optimism about their partnership as they aim to provide innovative biotherapeutic solutions to address unmet medical needs.
Read more →PLUR▲ +9.9%on this news
Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment
Pluri Inc. has appointed Alejandro Weinstein as the new Chairman of the Board, signaling a strategic shift aimed at unlocking value within the company. Weinstein, one of Pluri's largest shareholders, plans to enhance market positioning and realize the potential of Pluri's assets. As part of the leadership transition, outgoing Chairman Zami Aberman will move to the role of Vice Chairman. Additionally, Pluri has entered a private placement agreement to raise approximately $2.5 million to support its operations.
Read more →PLUR▼ -6.1%on this news· ran to -18% by day 3
Pluri and Subsidiaries Earn Multiple Industry Honors, Named as Overall BioAgriculture Company of the Year
Pluri Inc. has received multiple industry honors, including the title of Overall BioAgriculture Company of the Year from the Biotech Breakthrough Awards. Additionally, its subsidiaries Coffeesai Ltd. and Kokomodo Ltd. garnered significant recognition for innovations in sustainable food production and cellular agriculture technology, respectively. Pluri's CEO, Yaky Yanay, is set to accept the 2024 Egalitarian Employment Award on behalf of the company. These accolades highlight Pluri's strong position in the biotechnology sector and its commitment to developing impactful cell-based solutions.
Read more →PLUR▲ +6.2%on this newsshared move
Pluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative Skincare
Pluri Inc. has launched Cellav Health and Aesthetics Ltd., a wholly-owned subsidiary focused on regenerative skincare, following a partnership with Miss Universe Skincare. This collaboration aims to co-develop advanced skincare products utilizing Pluri's proprietary 3D cell expansion technology and is expected to launch its first product in 2026. The partnership is set to leverage Miss Universe Skincare's global distribution network, reaching a market projected to grow significantly in the coming years. This move aligns with Pluri's strategy to expand into high-demand, revenue-generating markets.
Read more →PLUR▲ +18.5%on this newsshared move
Leading Global Players Back and Fund Pluri’s Cell-Based Food and Agriculture Collaborations
Pluri, Inc. has entered significant collaborations across Asia, Europe, and the U.S. through its subsidiaries, aiming to innovate food and agriculture production with advanced cell expansion technologies. These partnerships are designed to enhance market presence in cultivated meat, cacao, and coffee industries, reflecting a growing demand for sustainable solutions. Each collaboration includes a proof-of-concept funded by global partners, indicating strong confidence in Pluri's technology.
Read more →PLUR▼ -5.1%on this news
Pluri Subsidiary Coffeesai and Instituto del Café de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in Mexico
Pluri Inc.'s subsidiary Coffeesai has partnered with the Instituto del Café de Chiapas to advance cell-based coffee manufacturing in Mexico. The collaboration outlines a three-phase roadmap focusing on cell line development, pilot-scale biofarming, and commercial-scale production. This initiative aims to leverage innovative biotechnology to create sustainable coffee solutions while addressing market demands and environmental challenges.
Read more →PLURPluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion
Pluri Inc. has reported significant growth in revenue, with nearly 400% increase in the first nine months of fiscal year 2025 compared to the previous year. The company is strategically entering the cultivated cacao and coffee markets, addressing global supply challenges. Additionally, Pluri is pursuing partnerships and has received further funding to support its initiatives in healthcare and AgTech. The CEO's letter emphasizes continued expansion efforts and the potential of its proprietary cell expansion technology.
Read more →PLUR▼ -13.7%on this news
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.
Pluri Inc. has completed the acquisition of approximately 71% of Kokomodo Ltd., a cultivated cacao AgFoodTech company, for $4.5 million. Kokomodo will operate independently under its current leadership while benefiting from Pluri's resources. This acquisition aims to enhance innovation in sustainable cacao production and address climate change impacts on traditional farming.
Read more →PLUR▼ -6%on this news
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel
Pluri Inc. has announced the granting of two patents for its immune cell expansion technologies in the U.S. and Israel. These patents focus on MAIT cells, which are crucial for treating solid tumors. The company aims to leverage its proprietary 3D cell expansion technology to enhance the scalability and efficacy of these immune cells for potential immunotherapy applications. This development positions Pluri favorably in the growing field of cancer treatment.
Read more →About Pluri Inc.
HeadquartersMATAM ADVANCED TECHNOLOGY PARK, HAIFA
BIOPHARMAWATCH ELITE PLUS
Trade the next PLUR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime